Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic